DHR Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Danaher (NYSE: DHR)
›
Danaher (NYSE: DHR) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 58,000 employees.
The shares were at 222.50 USD on 20 November 2026, up 3.6% over 52 weeks. Its 52-week range is 160.93 USD to 242.80 USD: the price is 8.4% below the high and 38.3% above the low.
At a market capitalisation of 160.10B USD, it trades at 37.7 times trailing earnings and 24.4 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 33.8, a premium of 12% for DHR. It pays a dividend yielding 0.70% (it pays out 25% of its earnings), against a median of 0.77% among the dividend payers in that peer group.
Danaher reports return on equity of 6.9%, an operating margin of 22.0% and revenue up 8.3% year over year.
Its debt exceeds its cash by 22.10B USD, a debt-to-equity ratio of 0.37. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 21 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 259.90 USD is 16.8% above the current price. The next earnings report is expected on 27 January 2027.